European Markets See Uptick Amid Signs of Government Funding Progress
European stock markets experienced a significant rise at the beginning of the new trading week. This surge was driven by expectations that a late Senate test vote on Sunday could lead to a bipartisan agreement to fund the government. The potential resolution brought renewed optimism to investors across different regions.
US stock futures also showed an upward trend, with European indices following closely. Germany’s DAX index climbed 1.5%, France’s CAC 40 gained 1.4%, and London’s FTSE 100 advanced 0.8% around 11:00 CET. This market movement indicated a positive shift in sentiment, as the possibility of ending the government shutdown began to take shape. The shutdown had previously hindered access to critical economic data, creating uncertainty for market participants.
Russ Mould, investment director at AJ Bell, highlighted that while the Senate vote was a crucial first step, there were still challenges ahead. He pointed out that the ongoing impasse had not only affected the broader economy but also led to delays in key data releases, such as those related to the jobs market. This lack of information created a high level of uncertainty, which is typically unfavorable for markets. Additionally, it hampered the Federal Reserve’s ability to make informed decisions regarding interest rates.
Mould noted that the positive reaction from investors was understandable given the signs of progress. Asian shares saw an increase, European indices showed strength, and US futures suggested potential gains when Wall Street opened later in the day.
Diageo Shares Rise on New Leadership Appointment
Meanwhile, shares of Diageo, a struggling drinks giant, surged by 6.4% in early trade. This increase came after the appointment of Dave Lewis, former CEO of Tesco, to lead the company. Diageo is one of the world’s largest beverage groups, known for its iconic brands such as Johnnie Walker, Guinness, Smirnoff, Tanqueray, Don Julio, and Baileys, which are sold in over 180 countries.
The company has faced declining drink consumption since the end of the COVID-19 pandemic. An end to the government shutdown is seen as beneficial for Diageo, as the United States is its largest market. Lewis, who will take over in January 2026, earned the nickname “Drastic Dave” for his role in revitalizing the supermarket chain.
Dan Coatsworth, head of markets at AJ Bell, described the appointment as a “significant hire and a pleasant surprise.” He explained that investors were excited about Diageo’s future under Lewis, noting that the stock had been unloved due to years of disappointment. However, he emphasized that Lewis would ultimately be judged based on actual results rather than just hope.
Currency Movements and Gold Prices
In terms of currency exchange rates, the dollar remained stable, with the euro hovering around $1.15. The Japanese yen saw a slight increase, reaching $154.1 or a 0.5% rise. The UK pound, however, weakened slightly against the dollar, dropping by 0.1% to $1.315.
Gold prices rose by approximately 1.8%, reaching around €3,521 per troy ounce (about €113 per gram and €113,200 per kilogram). Despite the easing of shutdown concerns, gold continued to be viewed as a safe haven for investments.
Tech and Pharmaceutical Sector Developments
Artificial intelligence and tech leaders showed resilience in pre-market trading, aligning with the broader risk-on sentiment. Reports indicated that Nvidia’s stock increased by roughly 3.5%.
This movement occurred within a larger global relief rally, as investors anticipated the potential end of the government shutdown. In other developments, shares of Danish pharmaceutical giant Novo Nordisk rose by 2.3% by midday in Europe after announcing a partnership with Indian drugmaker Emcure Pharmaceuticals to market its weight-loss treatment Wegovy under a new brand through an exclusive agreement.
However, Novo Nordisk failed in its attempt to acquire biotech firm Metsera. The New York-based biotech company, which develops promising obesity drugs, stated it would accept a revised offer from Pfizer of up to $10 billion (€8.65bn).